# OnCo record neotrip (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/neotrip/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "neotrip", "NCT02620280" ;
  schema:name "NeoTRIP (NeoTRIPaPDL1)"@en ;
  schema:alternateName "NeoTRIPaPDL1"@en, "NeoTRIP Michelangelo"@en ;
  schema:description "NeoTRIP added the immunotherapy atezolizumab to platinum chemotherapy before surgery without anthracyclines and did not significantly increase the share of women whose tumour disappeared (49 versus 44 percent); its main endpoint, whether fewer women relapse, is still awaited."@en ;
  schema:url <https://onco.cc/trials/neotrip/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT02620280>, <https://doi.org/10.1016/j.annonc.2022.02.004> ;
  onco:status "negative" ;
  onco:phase "3" ;
  onco:cancers <https://onco.cc/cancers/tnbc/>, <https://onco.cc/cancers/tnbc-early/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/technologies/platinum/>, <https://onco.cc/technologies/cytotoxic-chemotherapy/> ;
  onco:drugs <https://onco.cc/drugs/atezolizumab/>, <https://onco.cc/drugs/carboplatin/>, <https://onco.cc/drugs/nab-paclitaxel/> ;
  onco:institutions <https://onco.cc/institutions/fondazione-michelangelo/> ;
  onco:terms <https://onco.cc/terms/pcr/>, <https://onco.cc/terms/efs/> ;
  onco:trials <https://onco.cc/trials/impassion031/>, <https://onco.cc/trials/keynote-522/>, <https://onco.cc/trials/gepardouze/> .